Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A417PT | ISIN: US55234L2043 | Ticker-Symbol:
NASDAQ
04.06.25 | 22:00
22,820 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
LYRA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
LYRA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur LYRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoMicrocap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data9
MoWhy Is Lyra Therapeutics Stock Surging Over 400% On Monday?7
MoLyra Therapeutics stock soars on positive Phase 3 trial results11
LYRA THERAPEUTICS Aktie jetzt für 0€ handeln
MoLyra Therapeutics, Inc. - 8-K, Current Report1
MoLyra Therapeutics-Aktie steigt nach positiven Phase-3-Studienergebnissen stark an16
MoLyra Therapeutics reports positive phase 3 trial results for CRS treatment3
MoLyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)140ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)ENLIGHTEN...
► Artikel lesen
19.05.Lyra Therapeutics, Inc. - 8-K, Current Report12
07.05.Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 20257
06.05.Lyra Therapeutics, Inc. - 10-Q, Quarterly Report1
06.05.Lyra Therapeutics, Inc. - 8-K, Current Report1
06.05.Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update145WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory...
► Artikel lesen
13.03.Lyra Therapeutics GAAP EPS of -$1.43 misses by $0.10, revenue of $1.53M2
13.03.Lyra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
13.03.Lyra Therapeutics, Inc. - 10-K, Annual Report3
13.03.Lyra Therapeutics, Inc. - 8-K, Current Report1
13.03.Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update437Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities...
► Artikel lesen
10.01.Lyra Therapeutics, Inc. - 8-K, Current Report6
13.12.24Lyra Therapeutics, Inc. - 8-K, Current Report4
12.11.24Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update218Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension...
► Artikel lesen
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1